Stock Price Quote

LUPIN LTD.

NSE : LUPINBSE : 500257ISIN CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse : Lupin
BSE1937.40-22.6 (-1.15 %)
PREV CLOSE ( ) 1960.00
OPEN PRICE ( ) 1950.00
BID PRICE (QTY) 1936.35 (48)
OFFER PRICE (QTY) 1937.40 (2)
VOLUME 839
TODAY'S LOW / HIGH ( )1937.40 1950.00
52 WK LOW / HIGH ( )1900.3 2530
NSE1950.00-3.6 (-0.18 %)
PREV CLOSE( ) 1953.60
OPEN PRICE ( ) 1950.00
BID PRICE (QTY) 1948.20 (1)
OFFER PRICE (QTY) 1950.00 (31)
VOLUME 400
TODAY'S LOW / HIGH( ) 1950.00 1950.00
52 WK LOW / HIGH ( )1900 2529.5
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 01-03 1983
Management Info
Manju D Gupta - Chairman Nilesh Gupta - Managing Director
Registered Office

Address Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East),
Mumbai,
Maharashtra-400055

Phone 022 66402323

Email info@lupin.com

Website www.lupin.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

09Oct Lupin gets USFDA’s approval for Phyton
Lupin has received approval from the United States Food and Drug Adminis..
09Oct Lupin moves up on getting USFDA’s appr
Lupin is currently trading at Rs. 1953.60, up by 11.60 points or 0.60% f..
06Oct Lupin launches world’s first triple co
Lupin has launched Formoflo-G MDI, the world's first fixed-dose triple c..
06Oct Lupin inches up on launching world’s f
Lupin is currently trading at Rs. 2015.60, up by 5.60 points or 0.28% fr..
06Oct Lupin informs about press release
Lupin has informed that it enclosed a Press Release titled ‘Lupin Launch..

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit2714663665.6
Gross Profit 36100.6 76942.5
Operating Profit 38356.381163.3
Net Sales 71719195126.6

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  25910.70 (0.86%)
M.Cap ( in Cr)54588.08
Fredun Pharma (BSE)
peergroup  1506.70 (1.97%)
M.Cap ( in Cr)2523.96
Caplin Point Labs. (BSE)
peergroup  2388.05 (1.18%)
M.Cap ( in Cr)17940.66
NGL Fine-Chem (BSE)
peergroup  2894.00 (0.80%)
M.Cap ( in Cr)1773.65
Concord Biotech (BSE)
peergroup  1381.10 (0.94%)
M.Cap ( in Cr)14313.59

Shareholding Pattern

FI/BANKS/INSURANCE 6.98%
NON-INSTITUTION 6.08%
PROMOTERS 46.85%
MUTUAL FUNDS/UTI 14.84%
GOVERNMENT 0%
FII 0%

About Lupin Ltd.

Lupin Ltd. was incorporated in the year 1983. Its today's share price is 1937.4. Its current market capitalisation stands at Rs 89628.83 Cr. In the latest quarter, company has reported Gross Sales of Rs. 195804.9 Cr and Total Income of Rs.204525.3 Cr. The company's management includes Alfonso Zulueta, Mark D McDade, K B S Anand, Punita Lal, Anand Kripalu, Jeffrey Kindler, Ramesh Swaminathan, Nilesh Gupta, Manju D Gupta, Amit Kumar Gupta.

It is listed on the BSE with a BSE Code of 500257 , NSE with an NSE Symbol of LUPIN and ISIN of INE326A01037. It's Registered office is at Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East)Mumbai-400055, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Arora & Arora, BSR & Co LLP, Deloitte Haskins & Sells, Deloitte Haskins & Sells LLP, Deloittee Haskins & Sells, SS Kapoor & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.